Skip to main content

ADMA Biologics Value Stock - Dividend - Research Selection

Adma biologics

ISIN: US0008991046 , WKN: A12FAG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Transcript : ADMA Biologics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 10

2025-01-13
Presenter SpeechUnknown Analyst Good morning, everyone. My name is [ David Low]. I cover health care for JPMorgan out of Australia. And with today, I have the pleasure of introducing Adam Grossman,...

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

2025-01-13
FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million YE 2024 Total Cash Grew to More than $100 Million, an Increase of...

ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?

2025-01-10
ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.

Is ADMA Biologics, Inc. (ADMA) the Best Growth Stock to Buy Now Under $25?

2025-01-09
We recently compiled a list of the 12 Best Growth Stocks Under $25 to Buy Now. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against the other growth stocks. AI is the Most Defining Theme of 2025, Says Expert Most experts agree that the AI wave is […]

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

2025-01-08
Adma Biologics (ADMA) closed at $18.56 in the latest trading session, marking a +1.48% move from the prior day.

SpringWorks Therapeutics Stock Gets A RS Rating Lift

2025-01-08
SpringWorks Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

2025-01-08
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

High Growth Tech Stocks to Watch in January 2025

2025-01-07
The United States market has shown robust performance recently, with a 1.3% increase over the last week and a significant 24% rise over the past year, while earnings are anticipated to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation in line with these positive market trends.

ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025

2025-01-07
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ADMA’s presentation will be on Monday, January 13, 2025, at 10:30 a.m. PT.

Why Is ADMA Biologics, Inc. (ADMA) Among the Best Multibagger Stocks to Buy Right Now?

2025-01-01
We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against the other multibagger stocks. The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs. Much of this […]